Renalytix plc SEC filings RENXF
Renalytix plc has 233 filings in SEC EDGAR's recent list, going back to May 15, 2020. Its latest annual report, Form 10-K, was filed on Sep 30, 2024 for the period ended Jun 30, 2024. The latest quarterly report (Form 10-Q) was filed on Nov 19, 2024, covering the quarter ended Sep 30, 2024. The most recent current report (Form 8-K) was filed on Jan 16, 2025 (regulation fd disclosure). The company's fiscal year ends on June 30.
| Form | Description | Filed | Period |
|---|---|---|---|
| F-6 POS | Filing | Dec 3, 2025 | — |
| F-6 POS | Filing | Sep 4, 2025 | — |
| 424B3 | Prospectus | Jul 30, 2025 | — |
| POS AM | Post-effective amendment no. 1 to form s-3 | Jul 29, 2025 | — |
| POS AM | Post-effective amendment no. 1 to form s-3 | Jul 29, 2025 | — |
| POS AM | Post-effective amendment no. 1 to form s-3 | Jul 29, 2025 | — |
| POS AM | Post-effective amendment no. 2 to form f-3 on form s-3 | Jul 29, 2025 | — |
| POS AM | Post-effective amendment no. 3 to form f-3 on form s-3 | Jul 29, 2025 | — |
| S-8 POS | Registration statement | Jul 25, 2025 | — |
| S-8 POS | Post-effective amendment no. 1 to form s-8 | Jul 25, 2025 | — |
| 424B3 | Prospectus | Jun 28, 2024 | — |
| S-3/A | Filing | Jun 26, 2024 | — |
| S-3/A | Filing | Jun 14, 2024 | — |
| S-3 | Shelf registration | Jun 5, 2024 | — |
| 424B5 | Prospectus supplement | May 15, 2024 | — |
| 424B3 | Prospectus | May 8, 2024 | — |
| S-3 | Shelf registration | Apr 17, 2024 | — |
| 424B5 | Prospectus supplement | Apr 9, 2024 | — |
| S-3 | Shelf registration | Sep 28, 2023 | — |
| POS AM | Filing | Sep 28, 2023 | — |
| POS AM | Filing | Sep 28, 2023 | — |
| S-8 | Employee stock plan registration | Sep 28, 2023 | — |
| 424B3 | Prospectus | May 10, 2023 | — |
| F-3 | Shelf registration (foreign issuer) | May 2, 2023 | — |
| POS AM | Filing | Aug 1, 2022 | — |
| 424B3 | Prospectus | Jun 6, 2022 | — |
| F-3 | Shelf registration (foreign issuer) | May 27, 2022 | — |
| 424B3 | Prospectus | Jul 6, 2021 | — |
| S-8 | Employee stock plan registration | Sep 11, 2020 | — |
| 424B4 | Prospectus | Jul 17, 2020 | — |
| FWP | Free writing prospectus | Jul 17, 2020 | — |
| F-6/A | Filing | Jul 13, 2020 | — |
| F-1/A | Filing | Jul 13, 2020 | — |
| F-6 | Filing | Jul 7, 2020 | — |
| F-1 | Registration statement (foreign issuer) | Jun 24, 2020 | — |
Showing 35 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Services-Medical Laboratories (SIC 8071)
- Listed as
- RNLXY (OTC), RENXF (OTC)
- Fiscal year ends
- June 30
- Incorporated in
- United Kingdom
- Headquarters
- London
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1811115
- Former names
- Renalytix AI plc (until Jun 25, 2021)
Other Services-Medical Laboratories companies
- Natera, Inc. NTRA
- Labcorp Holdings Inc. LH
- Quest Diagnostics Inc DGX
- Guardant Health, Inc. GH
- Caris Life Sciences, Inc. CAI
- GRAIL, Inc. GRAL
- RadNet, Inc. RDNT
- BillionToOne, Inc. BLLN
Source: SEC EDGAR filings. This is company-reported data, not investment advice.